Follows lung cancer patients in Germany to study testing, treatment and outcomes
Records molecular tests, treatments and outcomes in adults with lung cancer.
Plain-language title generated from the registry record
Registry title: Clinical Research Platform Into Molecular Testing, Treatment and Outcome of (Non-)Small Cell Lung Carcinoma Patients
Key facts
- Where
- Oldenburg, GermanySee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with non-small cell lung cancer (any stage) or small cell lung cancer who are starting treatment in Germany. It collects data on tests, treatment and outcome.
- Age
- 18 years or older
- Sex
- All sexes can join.
- Disease stage
- Non-small cell lung cancer stage IV (main project), non-small cell lung cancer stage I-III, or small cell lung cancer (satellite projects). Stage by UICC8.
- Earlier treatment
- Informed consent must be given within four weeks after starting the first treatment. For stage I-III, if the first treatment is surgery, within 3 months after the start of surgery. Stage IV needs systemic therapy; stage I-III and small cell lung cancer need systemic therapy, radiation therapy and/or surgery.
Read by machine on 9 November 2026.
Where in Germany
- Pius-HospitalOldenburg, GermanyTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- AIO-Studien-gGmbH
- Trial code
- NCT02622581
- Record updated
- 9 October 2026
- Original description
Open, non-interventional, prospective, multi-center clinical research platform with the main objective to assess molecular biomarker testing, treatment and outcome of patients with NSCLC or SCLC in GermanyRead full original descriptionShow less
Clinical Research Platform Into Molecular Testing, Treatment and Outcome of (Non-)Small Cell Lung Carcinoma Patients
Open, non-interventional, prospective, multi-center clinical research platform with the main objective to assess molecular biomarker testing, treatment and outcome of patients with NSCLC or SCLC in Germany
Inclusion: Patients who meet all of the following criteria are eligible for the project:; Age ≥ 18 years; Able to understand and willing to sign written Informed Consent and to complete patient-reported-outcome assessment instruments; Main project (NSCLC Stage IV):; Confirmed non-small cell lung cancer (NSCLC); Stage IV (UICC8); Systemic therapy; Informed consent no later than four weeks after start of first-line systemic treatment; Satellite NSCLC Stage I-III:; Confirmed non-small cell lung cancer (NSCLC); Informed consent no later than four weeks after start of first anti-tumor treatment (including surgery and radiotherapy) or if first treatment is surgery no longer than 3 months after start of surgery; Stage I-III (UICC8); Systemic (chemo)therapy and/or radiation therapy and/or surgery; Satellite SCLC; Confirmed Small cell lung cancer (SCLC); Informed consent no later than four weeks after start of first anti-tumor treatment; Systemic (chemo)therapy and/or radiation therapy and/or surgery.
Exclusion: none.